Skip to results
Modify your search
NARROW
1-20 of 20
Authors: Rimas V Lukas
Journal Article
ACCEPTED MANUSCRIPT
The excitatory milieu in glioma: mechanisms and therapeutic avenues Get access
Neuro-Oncology, noaf063, https://doi.org/10.1093/neuonc/noaf063
Published: 18 April 2025
Journal Article
CNSC-47. SENOLYTICS ERADICATE SENESCENT MICROGLIA IN THE BRAIN PARENCHYMA AND IMPROVE SURVIVAL IN OLDER ADULT MICE WITH GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii51, https://doi.org/10.1093/neuonc/noae165.0203
Published: 11 November 2024
Journal Article
IMMU-19. PRECLINICAL THERAPEUTIC ACTIVITY AND PET IMAGING OF STING AGONIST 8803 IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii156, https://doi.org/10.1093/neuonc/noae165.0612
Published: 11 November 2024
Journal Article
EDITOR'S CHOICE
Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?
Neuro-Oncology, Volume 27, Issue 1, January 2025, Pages 33–49, https://doi.org/10.1093/neuonc/noae193
Published: 19 October 2024
Journal Article
LONG-TERM POST-MARKETING SURVEILLANCE DATA FROM ELDERLY PATIENTS WITH CENTRAL NERVOUS SYSTEM MALIGNANCIES TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) THERAPY
Neuro-Oncology, Volume 25, Issue Supplement_3, October 2023, Page iii2, https://doi.org/10.1093/neuonc/noad147.007
Published: 16 September 2023
Journal Article
TRLS-07. GLOBAL POST-MARKETING SURVEILLANCE DATA FROM PEDIATRIC AND ADULT PATIENTS WITH CENTRAL NERVOUS SYSTEM MALIGNANCIES TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) THERAPY BETWEEN 2011–2022
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i80, https://doi.org/10.1093/neuonc/noad073.310
Published: 12 June 2023
Journal Article
Neurological applications of belzutifan in von Hippel-Lindau disease
Neuro-Oncology, Volume 25, Issue 5, May 2023, Pages 827–838, https://doi.org/10.1093/neuonc/noac234
Published: 10 October 2022
Journal Article
Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas
Neuro-Oncology, Volume 25, Issue 3, March 2023, Pages 508–519, https://doi.org/10.1093/neuonc/noac206
Published: 17 August 2022
Journal Article
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics
Neuro-Oncology, Volume 25, Issue 3, March 2023, Pages 557–565, https://doi.org/10.1093/neuonc/noac195
Published: 10 August 2022
Journal Article
Leptomeningeal metastases—What outcomes should we measure and how?
Neuro-Oncology, Volume 24, Issue 10, October 2022, Pages 1736–1737, https://doi.org/10.1093/neuonc/noac101
Published: 14 April 2022
Journal Article
Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 951–963, https://doi.org/10.1093/neuonc/noab271
Published: 26 November 2021
Journal Article
BIOM-31. ERK1/2 PHOSPHORYLATION PREDICTS SURVIVAL FOLLOWING ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi17, https://doi.org/10.1093/neuonc/noab196.062
Published: 12 November 2021
Journal Article
Essential oils for blood-brain barrier disruption: Preclinical studies of NEO100 in breast cancer brain metastases
Neuro-Oncology, Volume 23, Issue 10, October 2021, Pages 1621–1622, https://doi.org/10.1093/neuonc/noab167
Published: 09 July 2021
Journal Article
Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas
Neuro-Oncology, Volume 22, Issue 4, April 2020, Pages 470–479, https://doi.org/10.1093/neuonc/noz216
Published: 10 November 2019
Journal Article
EDITOR'S CHOICE
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients
Neuro-Oncology, Volume 21, Issue 12, December 2019, Pages 1498–1508, https://doi.org/10.1093/neuonc/noz119
Published: 04 July 2019
Journal Article
Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system
Neuro-Oncology, Volume 20, Issue 9, September 2018, Pages 1197–1206, https://doi.org/10.1093/neuonc/noy051
Published: 05 April 2018
Journal Article
ATIM-26. A PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN ADULT RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi32, https://doi.org/10.1093/neuonc/nox168.121
Published: 06 November 2017
Journal Article
ACTR-88. A PHASE II STUDY OF THE EFFICACY OF HYPOFRACTIONATED RADIATION THERAPY WITH BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY MAINTENANCE TEMOZOLOMIDE AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Pages vi19–vi20, https://doi.org/10.1093/neuonc/nox168.073
Published: 06 November 2017
Journal Article
TMOD-17. BRAIN TUMOR PATIENT DERIVED XENOGRAFT FROM LUNG TUMOR METASTASIS: ESTABLISHMENT AND CHARACTERIZATION
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi258, https://doi.org/10.1093/neuonc/nox168.1055
Published: 06 November 2017
Journal Article
IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA
Neuro-Oncology, Volume 17, Issue suppl_5, November 2015, Page v109, https://doi.org/10.1093/neuonc/nov218.08
Published: 09 November 2015
